• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过生物信息学方法分析白细胞介素 1 受体拮抗剂 (IL1RN) 在甲状腺乳头状癌中的表达及潜在分子机制。

Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.

机构信息

Department of Vascular and Thyroid Surgery, The First Hospital, China Medical University, Shenyang, China.

出版信息

BMC Cancer. 2020 Nov 25;20(1):1143. doi: 10.1186/s12885-020-07620-8.

DOI:10.1186/s12885-020-07620-8
PMID:33238942
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7687764/
Abstract

BACKGROUND

Interleukin-1 receptor antagonist (IL1RN) has been reported as a biomarker of many cancers. However, the biological function of IL1RN in papillary thyroid carcinoma (PTC) remains undetermined.

METHODS

We obtained IL1RN expression data from The Cancer Genome Atlas (TCGA) database. Enrichment analysis of coexpressed genes and IL1RN methylation analysis were performed via LinkedOmics. The correlations between IL1RN and immune infiltrates were investigated via ESTIMATE, TIMER and TISIDB. We analyzed the association of IL1RN expression with pancancer overall survival (OS) via Gene Expression Profiling Interactive Analysis (GEPIA).

RESULTS

IL1RN showed higher expression levels and lower methylation levels in PTC tissues than in normal tissues. Higher IL1RN expression was significantly associated with shorter progression-free survival (PFS), advanced tumor stage, tumor metastasis, increased incidence of BRAF mutations, and decreased incidence of N-RAS and H-RAS mutations. Genes coexpressed with IL1RN participate primarily in immune-related pathways. IL1RN expression positively correlated with immune infiltration, tumor progression and poor OS for all cancers.

CONCLUSIONS

IL1RN is a good prognostic and diagnostic biomarker for PTC. IL1RN may promote thyroid cancer progression through immune-related pathways. Methylation may act as an upstream regulator of IL1RN expression and biological function. Additionally, IL1RN was shown to have broad prognostic value in a pancancer cohort.

摘要

背景

白细胞介素-1 受体拮抗剂 (IL1RN) 已被报道为许多癌症的生物标志物。然而，IL1RN 在甲状腺乳头状癌 (PTC) 中的生物学功能仍未确定。

方法

我们从癌症基因组图谱 (TCGA) 数据库中获取了 IL1RN 表达数据。通过 LinkedOmics 进行共表达基因的富集分析和 IL1RN 甲基化分析。通过 ESTIMATE、TIMER 和 TISIDB 研究了 IL1RN 与免疫浸润物的相关性。我们通过基因表达谱交互式分析 (GEPIA) 分析了 IL1RN 表达与泛癌总体生存 (OS) 的关联。

结果

与正常组织相比，PTC 组织中 IL1RN 的表达水平更高，甲基化水平更低。较高的 IL1RN 表达与较短的无进展生存期 (PFS)、较高级别的肿瘤分期、肿瘤转移、BRAF 突变发生率增加以及 N-RAS 和 H-RAS 突变发生率降低显著相关。与 IL1RN 共表达的基因主要参与免疫相关途径。IL1RN 的表达与免疫浸润、肿瘤进展和所有癌症的不良 OS 呈正相关。

结论

IL1RN 是 PTC 的良好预后和诊断生物标志物。IL1RN 可能通过免疫相关途径促进甲状腺癌的进展。甲基化可能作为 IL1RN 表达和生物学功能的上游调节剂。此外，IL1RN 在泛癌队列中表现出广泛的预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/c1a7ae3aba61/12885_2020_7620_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/8b459e0c102b/12885_2020_7620_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/b62dcb0e1868/12885_2020_7620_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/c2c86fdc3079/12885_2020_7620_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/acf6ea6fb74e/12885_2020_7620_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/c1a7ae3aba61/12885_2020_7620_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/8b459e0c102b/12885_2020_7620_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/b62dcb0e1868/12885_2020_7620_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/c2c86fdc3079/12885_2020_7620_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/acf6ea6fb74e/12885_2020_7620_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f4/7687764/c1a7ae3aba61/12885_2020_7620_Fig5_HTML.jpg

相似文献

1
Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.通过生物信息学方法分析白细胞介素 1 受体拮抗剂 (IL1RN) 在甲状腺乳头状癌中的表达及潜在分子机制。
BMC Cancer. 2020 Nov 25;20(1):1143. doi: 10.1186/s12885-020-07620-8.
2
Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer Bioinformatics Methods.甲状腺乳头状癌中 TREM-1 过表达的预后价值及潜在分子机制分析 生物信息学方法。
Front Endocrinol (Lausanne). 2021 May 27;12:646793. doi: 10.3389/fendo.2021.646793. eCollection 2021.
3
Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.具有高肿瘤突变负担的甲状腺乳头状癌预后不良。
Int Immunopharmacol. 2020 Dec;89(Pt B):107090. doi: 10.1016/j.intimp.2020.107090. Epub 2020 Oct 19.
4
Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients.ESR1 基因和 ESR 比值（ESR1/ESR2）的上调与甲状腺乳头状癌预后不良相关：雌激素受体 α/β表达对甲状腺乳头状癌患者临床结局的影响。
Ann Surg Oncol. 2017 Nov;24(12):3754-3762. doi: 10.1245/s10434-017-5780-z. Epub 2017 Jan 25.
5
Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.肿瘤突变负荷通过基因和免疫微环境变化预测甲状腺乳头状癌复发
Front Endocrinol (Lausanne). 2021 Jun 23;12:674616. doi: 10.3389/fendo.2021.674616. eCollection 2021.
6
Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.转录组分析确定了一个代谢基因特征，表明甲状腺乳头状癌去分化。
J Clin Endocrinol Metab. 2019 Sep 1;104(9):3713-3725. doi: 10.1210/jc.2018-02686.
7
Identification of key genes of papillary thyroid carcinoma by integrated bioinformatics analysis.整合生物信息学分析鉴定甲状腺乳头状癌的关键基因。
Biosci Rep. 2020 Aug 28;40(8). doi: 10.1042/BSR20201555.
8
The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.整合素受体和骨桥蛋白在甲状腺恶性肿瘤中的表达谱因肿瘤进展速度和BRAF V600E突变的存在而有所不同。
Surg Oncol. 2018 Dec;27(4):702-708. doi: 10.1016/j.suronc.2018.09.007. Epub 2018 Sep 22.
9
Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.miR-146b 表达的预后意义及其在甲状腺乳头状癌中的功能作用。
J Clin Endocrinol Metab. 2013 Feb;98(2):E196-205. doi: 10.1210/jc.2012-2666. Epub 2012 Dec 21.
10
Development of prognostic signatures for intermediate-risk papillary thyroid cancer.中危乳头状甲状腺癌预后特征的开发
BMC Cancer. 2016 Sep 15;16(1):736. doi: 10.1186/s12885-016-2771-6.

引用本文的文献

1
Identification of oxidative stress-related subgroups and signature genes for the prediction of prognosis and immune microenvironment in thyroid cancer.鉴定氧化应激相关亚组和特征基因以预测甲状腺癌的预后和免疫微环境
Mol Genet Genomics. 2025 Apr 30;300(1):46. doi: 10.1007/s00438-025-02252-8.
2
Comparison of 46 Cytokines in Peripheral Blood Between Patients with Papillary Thyroid Cancer and Healthy Individuals with AI-Driven Analysis to Distinguish Between the Two Groups.甲状腺乳头状癌患者与健康个体外周血中46种细胞因子的比较及人工智能驱动分析对两组的区分
Diagnostics (Basel). 2025 Mar 20;15(6):791. doi: 10.3390/diagnostics15060791.
3

本文引用的文献

1
TISIDB: an integrated repository portal for tumor-immune system interactions.TISIDB：一个用于肿瘤-免疫系统相互作用的综合知识库门户。
Bioinformatics. 2019 Oct 15;35(20):4200-4202. doi: 10.1093/bioinformatics/btz210.
2
Evolving Understanding of the Epidemiology of Thyroid Cancer.甲状腺癌流行病学认识的演变。
Endocrinol Metab Clin North Am. 2019 Mar;48(1):23-35. doi: 10.1016/j.ecl.2018.10.002. Epub 2018 Dec 23.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Association of Variants in (rs2234663) and (rs1143627, rs16944) and Interleukin-1β Levels with Colorectal Cancer: Experimental Study and In Silico Analysis.
（rs2234663）和（rs1143627、rs16944）基因变体及白细胞介素-1β水平与结直肠癌的关联：实验研究和计算机模拟分析
Genes (Basel). 2024 Nov 27;15(12):1528. doi: 10.3390/genes15121528.
4
DNA methylation analysis of multiple genes in thymic epithelial tumors.胸腺瘤中多个基因的DNA甲基化分析
Epigenomics. 2024 Nov-Nov;16(21-22):1337-1350. doi: 10.1080/17501911.2024.2419362. Epub 2024 Nov 8.
5
Coagulation-related genes for thyroid cancer prognosis, immune infltration, staging, and drug sensitivity.甲状腺癌预后、免疫浸润、分期和药物敏感性的相关凝血基因。
Front Immunol. 2024 Oct 21;15:1462755. doi: 10.3389/fimmu.2024.1462755. eCollection 2024.
6
Establishing a Novel Pyroptosis-Related Gene Signature and Predicting Chemical Drugs for Papillary Thyroid Cancer.建立一种新型的焦亡相关基因特征并预测甲状腺乳头状癌的化学药物。
Curr Pharm Biotechnol. 2024 Nov 1. doi: 10.2174/0113892010325685241029113633.
7
Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment.衰老通过诱导免疫抑制性肿瘤微环境来导致免疫疗法耐药性。
Nat Commun. 2024 Mar 18;15(1):2435. doi: 10.1038/s41467-024-46769-9.
8
Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors.实体瘤治疗及预后预测中T细胞增殖调节因子的综述
Heliyon. 2023 Oct 29;9(11):e21329. doi: 10.1016/j.heliyon.2023.e21329. eCollection 2023 Nov.
9
The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma.血浆补体因子 B（CFB）在甲状腺癌中的预后价值。
Bioengineered. 2021 Dec;12(2):12854-12866. doi: 10.1080/21655979.2021.2005745.
10
Identification and validation of a pyroptosis-related prognostic signature for thyroid cancer.甲状腺癌焦亡相关预后标志物的鉴定与验证
Cancer Cell Int. 2021 Oct 9;21(1):523. doi: 10.1186/s12935-021-02231-0.
全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
LinkedOmics: analyzing multi-omics data within and across 32 cancer types.LinkedOmics：在 32 种癌症类型内和类型间分析多组学数据。
Nucleic Acids Res. 2018 Jan 4;46(D1):D956-D963. doi: 10.1093/nar/gkx1090.
5
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.TIMER：用于肿瘤浸润免疫细胞综合分析的网络服务器。
Cancer Res. 2017 Nov 1;77(21):e108-e110. doi: 10.1158/0008-5472.CAN-17-0307.
6
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.GEPIA：一个用于癌症和正常基因表达谱分析及交互式分析的网络服务器。
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. doi: 10.1093/nar/gkx247.
7
Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.甲状腺癌：风险分层管理与个体化治疗。
Clin Cancer Res. 2016 Oct 15;22(20):5012-5021. doi: 10.1158/1078-0432.CCR-16-0484.
8
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南：美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
9
Interleukin-1 receptor antagonist (IL1RN) is associated with suppression of early carcinogenic events in human oral malignancies.白细胞介素-1受体拮抗剂（IL1RN）与人类口腔恶性肿瘤早期致癌事件的抑制有关。
Int J Oncol. 2015 May;46(5):1978-84. doi: 10.3892/ijo.2015.2917. Epub 2015 Mar 4.
10
Integrated genomic characterization of papillary thyroid carcinoma.甲状腺乳头状癌的综合基因组特征分析
Cell. 2014 Oct 23;159(3):676-90. doi: 10.1016/j.cell.2014.09.050.